JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Arcus Biosciences Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

16.76 0.96

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

16.4

Max

16.95

Pagrindiniai rodikliai

By Trading Economics

Pardavimai

132M

160M

Darbuotojai

627

EBITDA

126M

4M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+79.11% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

882M

1.9B

Ankstesnė atidarymo kaina

15.8

Ankstesnė uždarymo kaina

16.76

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Arcus Biosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-23 20:49; UTC

Uždarbis

Correction to Thermo Fisher Article on Oct. 22

2025-10-23 23:51; UTC

Rinkos pokalbiai

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

2025-10-23 23:49; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-23 23:49; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

2025-10-23 23:37; UTC

Rinkos pokalbiai

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

2025-10-23 22:58; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2025-10-23 22:57; UTC

Rinkos pokalbiai

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

2025-10-23 22:49; UTC

Įsigijimai, susijungimai, perėmimai

How Trump Sparked a New Era of State Capitalism -2-

2025-10-23 22:49; UTC

Įsigijimai, susijungimai, perėmimai

How Trump Sparked a New Era of State Capitalism -- Barrons.com

2025-10-23 22:17; UTC

Uždarbis

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

2025-10-23 21:41; UTC

Uždarbis

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

2025-10-23 21:05; UTC

Uždarbis

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

2025-10-23 20:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-10-23 20:50; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2025-10-23 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-23 20:35; UTC

Uždarbis

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

2025-10-23 20:28; UTC

Uždarbis

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

2025-10-23 20:15; UTC

Rinkos pokalbiai
Uždarbis

Global Commodities Roundup: Market Talk

2025-10-23 20:10; UTC

Uždarbis

Newmont Mining 3Q Adj EPS $1.71

2025-10-23 20:10; UTC

Uždarbis

Newmont Mining 3Q Sales $5.52B

2025-10-23 20:10; UTC

Uždarbis

Newmont Mining 3Q EPS $1.67

2025-10-23 20:09; UTC

Uždarbis

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

2025-10-23 20:07; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2025-10-23 20:07; UTC

Rinkos pokalbiai
Uždarbis

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

2025-10-23 20:07; UTC

Uždarbis

Blackstone Looks to IPOs for Investment Exits -- Update

2025-10-23 20:05; UTC

Uždarbis

Intel 3Q Gross Margin 38.2% >INTC

2025-10-23 20:04; UTC

Uždarbis

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

2025-10-23 20:04; UTC

Uždarbis

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

2025-10-23 20:04; UTC

Uždarbis

Intel: 4Q Guidance Excludes Altera >INTC

2025-10-23 20:04; UTC

Uždarbis

Intel Sees 4Q Adj EPS 8c >INTC

Akcijų palyginimas

Kainos pokytis

Arcus Biosciences Inc Prognozė

Kainos tikslas

By TipRanks

79.11% į viršų

12 mėnesių prognozė

Vidutinis 32.33 USD  79.11%

Aukščiausias 54 USD

Žemiausias 14 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Arcus Biosciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

11

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

8.01 / 8.75Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Neutral Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
help-icon Live chat